Gero

Unveiling the Rules of Life: Entropy Identified as the Key to Human Aging "Gero's latest research challenges everything we thought we knew about aging. By pinpointing entropy as the core driver of age-related decline, scientists suggest we could unlock unprecedented methods to extend human healthspan and lifespan. This paradigm shift offers a new lens on biological design and paves the way for therapies that could radically slow or even halt the aging process within our lifetimes." The unique insights into aging place Gero in a highly competitive position for discovering new targets for age-related diseases. There are two manifestations of aging: reversible and irreversible. The reversible part is associated with key age-related diseases. The irreversible part can only be slowed down. Slowing this process is the only way to significantly extend life and maintain functional performance beyond 120 years. Now we understand why pharma often fails when tackling age-related diseases. In their search for targets, they often focus on the irreversible aspects of aging—essentially trying to reverse the irreversible. Our technology platform enables us to distinguish between the irreversible effects of aging and reversible disease phenotypes, allowing us to identify the most actionable therapeutic targets. This is the approach Gero has taken in its collaboration with Pfizer, focusing on fibrosis. Simultaneously, we have identified targets for therapies aimed at slowing down or even stopping aging—an endeavor that aligns with our core mission. Additionally, we are working on several projects to revolutionize the treatment of major age-related diseases, grounded in our deep understanding of their underlying nature. As we prepare for our next funding round, we invite investors to engage in early discussions and join us in advancing this mission. We are also open to early-stage drug discovery collaborations with pharmaceutical companies, where we identify new targets for age-related diseases and design active molecules to address them. The links to the Longevity Technology publication and our collaboration with Pfizer are provided in the first comment. Like and share to help spread the word and be part of the movement!

This work will shape the future of aging science and the longevity industry, eventually becoming a part of textbooks. Life as we know it will never be the same. Huge kudos to Peter Fedichev and the entire team! "Better late than ever, ladies and gents - it’s been a while since 2022, when this paper was first posted on a preprint server, and now it’s officially published in Aging Research — without compromising the original statements and predictions (huge thanks to Vera Gorbunova and the team! Link in the first comment). 2 years later, the conclusions hold strong: – Aging in humans (and most mammals) isn’t the same as in short-lived species like mice. – In mice, aging is a "simple" dynamic instability of the organism state - a regulatory error catastrophe, and it's almost entirely reversible. The hallmarks of aging in mice are highly correlated—targeting one impacts all the others, and the effects of short treatments persist. – In humans, aging is entropic. The number of relevant hallmarks of aging is vast, making aging mosaic—microscopically different across systems and cells within the same organism. This complexity makes it harder to control and reverse. – Drugs that work in mice will produce only short-lived and weak effects on human lifespan. Most don’t target entropic aging (check out the preprint, link in the first comment). – We’re seeing more examples of anti-aging drugs that work in mice but don’t affect entropic aging in other species—stay tuned! – A new class of drugs is emerging that slows down aging in humans without fully reversing it—this is the key to breaking the 120–150 year maximum lifespan limit that our team established in 2021 for drugs that target diseases but do not target aging itself. This finding is now reconfirmed in this paper using DNAm datasets. This isn’t your typical biomarkers of aging paper—it’s a comprehensive theory of aging in humans, testable and making novel predictions, paving the way for stronger therapeutics." The link is in the first comment

New GeroSense website is now live!

At Gero and GeroSense, we are looking for a junior to mid-level Data Scientist/Machine Learning Engineer/Researcher for a 2-month project with the potential for a permanent role with a salary increase based on performance. Experience with wearable and/or longitudinal data is a plus. Key skills: Python (PyTorch, TensorFlow, SciPy, Pandas, sklearn), signal processing, SQL (optional), version control systems (Git), and AWS. Please send your CVs to dreamjob@gerosense.ai

FAQ concerning aging theory created at Gero

The quest to extend healthy human lifespan has reached a critical juncture, with two competing theories vying for dominance: Can we reverse aging, or slow it down and even halt it? This question will take center stage in a landmark debate, "How to Defeat Aging," featuring scientific heavyweights Aubrey de Grey from Longevity Escape Velocity Foundation and Peter Fedichev from Gero. We are happy to invite you to this unique, friendly but fair debate on longevity, hosted by the Foresight Institute, Say Forever, and Open Longevity. The event will be held both online and live in San Francisco on May 27, 2024. Let’s surface the hard problems and conflicting concepts in the field – and possibly find some common ground! Find out more and join the event by the link https://lnkd.in/gDB-njXf

I will be in Amsterdam from 1 to 6 May. Who should I meet in the Longevity, Healthtech, and Health/Life Insurance industries?

More details on our nonprofit initiative GeroSense Studies Featuring Aleksandr Sviridov and Peter Fedichev interviewed by brilliant Arkadi Mazin.

We launch a very important initiative to crowdsource the science of longevity! Please help us spread the word (like & share) and contribute your data!

Full episode links: https://lnkd.in/eqTy85_f https://lnkd.in/etrJWQ9g Discussed how to transition your career to longevity with a leading AI recruiter Chris Coyne. I reflected on my experience in longevity biotechnology and shared some interesting facts about Gero, GeroSense, and the longevity biotechnology industry. I also share some 80/20 longevity tips that I apply today to increase my healthy life expectancy by 5-10 years. Follow Chris and his new venture, NeuralRec, to find the best AI engineering talent (if you are CxO) or hot ML/DL/DS vacancies (if you are an engineer). Honorable mentions to jump-start your longevity career include VitaDAO and Longevity Biotech Fellowship.